Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Liso-cel induces rapid uMRD: TRANSCEND-CLL-004 update

Tanya Siddiqi, MD, City of Hope, Duarte, CA, presents the latest updates from the TRANSCEND-CLL-004 trial (NCT03331198) of lisocabtagene maraleucel in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). She covers the exciting rapid, undetectable MRD responses observed in patients with relapsed/refractory CLL/SLL, and discusses the safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.